Nephros (NEPH) Competitors $4.89 -0.44 (-8.26%) Closing price 04:00 PM EasternExtended Trading$4.97 +0.08 (+1.64%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NEPH vs. TLSI, INGN, NNOX, CVRX, CV, NYXH, SKIN, INFU, ELMD, and BSGMShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include TriSalus Life Sciences (TLSI), Inogen (INGN), Nano-X Imaging (NNOX), CVRx (CVRX), CapsoVision (CV), Nyxoah (NYXH), Beauty Health (SKIN), InfuSystem (INFU), Electromed (ELMD), and Biosig Technologies (BSGM). These companies are all part of the "medical equipment" industry. Nephros vs. Its Competitors TriSalus Life Sciences Inogen Nano-X Imaging CVRx CapsoVision Nyxoah Beauty Health InfuSystem Electromed Biosig Technologies Nephros (NASDAQ:NEPH) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation. Which has more risk & volatility, NEPH or TLSI? Nephros has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Which has stronger valuation & earnings, NEPH or TLSI? Nephros has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNephros$14.16M3.66$70K$0.1240.75TriSalus Life Sciences$29.43M8.51-$30.05M-$1.18-4.25 Does the media refer more to NEPH or TLSI? In the previous week, TriSalus Life Sciences had 2 more articles in the media than Nephros. MarketBeat recorded 3 mentions for TriSalus Life Sciences and 1 mentions for Nephros. Nephros' average media sentiment score of 0.87 beat TriSalus Life Sciences' score of 0.57 indicating that Nephros is being referred to more favorably in the media. Company Overall Sentiment Nephros Positive TriSalus Life Sciences Positive Is NEPH or TLSI more profitable? Nephros has a net margin of 7.95% compared to TriSalus Life Sciences' net margin of -86.61%. Nephros' return on equity of 14.89% beat TriSalus Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Nephros7.95% 14.89% 11.64% TriSalus Life Sciences -86.61%N/A -116.50% Do institutionals & insiders hold more shares of NEPH or TLSI? 41.1% of Nephros shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate NEPH or TLSI? Nephros presently has a consensus price target of $5.50, suggesting a potential upside of 12.47%. TriSalus Life Sciences has a consensus price target of $10.90, suggesting a potential upside of 117.13%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than Nephros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67TriSalus Life Sciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00 SummaryNephros and TriSalus Life Sciences tied by winning 8 of the 16 factors compared between the two stocks. Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.50M$10.91B$6.11B$10.51BDividend YieldN/A1.88%5.73%4.81%P/E Ratio40.7513.8063.4522.93Price / Sales3.6626.54609.45131.82Price / Cash266.3525.0337.1661.22Price / Book6.043.4112.246.52Net Income$70K$210.63M$3.32B$276.75M7 Day Performance-9.44%0.03%0.76%0.92%1 Month Performance14.52%0.19%8.03%4.20%1 Year Performance226.00%-9.15%71.13%37.86% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros2.8842 of 5 stars$4.89-8.3%$5.50+12.5%+255.3%$56.50M$14.16M40.7530Short Interest ↓Gap UpTLSITriSalus Life Sciences2.284 of 5 stars$4.68+1.1%$10.90+132.9%+5.8%$233.64M$29.43M-3.97106Short Interest ↑INGNInogen3.8691 of 5 stars$8.64+2.4%$11.00+27.4%-9.3%$233.49M$335.70M-8.151,030Analyst ForecastNNOXNano-X Imaging2.5119 of 5 stars$3.94-4.7%$8.50+116.0%-31.3%$227.94M$11.89M-4.38190CVRXCVRx2.6001 of 5 stars$8.56-2.0%$14.00+63.6%+13.8%$224.89M$51.29M-4.10160CVCapsoVisionN/A$4.75+3.9%$5.50+15.8%N/A$222.18M$12.52M0.0090Short Interest ↑NYXHNyxoah2.5576 of 5 stars$6.48+11.6%$15.00+131.7%-37.9%$220.54M$4.89M-2.82110Gap UpHigh Trading VolumeSKINBeauty Health2.1183 of 5 stars$1.68+0.3%$2.81+67.9%-11.7%$212.42M$334.30M-5.981,030INFUInfuSystem4.0622 of 5 stars$10.25-2.4%$13.50+31.8%+31.6%$209.26M$139.89M170.78410Short Interest ↑ELMDElectromed3.3792 of 5 stars$24.79+0.1%$36.25+46.3%+5.4%$207.77M$64M33.07160News CoverageBSGMBiosig Technologies1.6016 of 5 stars$6.35+42.6%$10.00+57.6%+1,852.3%$199.35M$13K0.0050Gap DownHigh Trading Volume Related Companies and Tools Related Companies TriSalus Life Sciences Competitors Inogen Competitors Nano-X Imaging Competitors CVRx Competitors CapsoVision Competitors Nyxoah Competitors Beauty Health Competitors InfuSystem Competitors Electromed Competitors Biosig Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEPH) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
